RINAZINA ® Nafazolina

RINAZINA® is a drug based on naphazoline nitrate

THERAPEUTIC GROUP: Nasal decongestants

IndicationsAction mechanismStudies and clinical effectiveness Usage and dosage instructionsWarnings Pregnancy and lactationInteractionsContraindicationsUndesirable effects

Directions RINAZINA ® Nafazolina

RINAZINA® is indicated as a nasal decongestant during upper respiratory tract infections.

Mechanism of action RINAZINA ® Nafazolina

RINAZINA®, a medicinal product based on naphazoline, is a drug used as a decongestant of the nasal mucosa during respiratory infections such as sinusitis, pharyngitis and allergic rhinitis.

Like the other sympathomimetic drugs, also Naphazoline, following topical administration, interacts with the alpha-one receptors of the vascular smooth muscle, causing vasoconstriction of the small mucosal vessels.

This effect guarantees the reduction of edema and mucus secretion with consequent unblocking of the upper respiratory tract and restoration of the normal ventilatory flow.

Topical use in addition to ensuring an optimization of the therapeutic effect, concentrating the drug directly on site, minimizes the potential systemic side effects ensuring a safe use of the product.

Studies carried out and clinical efficacy

USE OF NAFAZOLINA IN POST-OPERATIVE PHASES

Can J Anaesth. 2009 Feb; 56 (2): 102-8. doi: 10.1007 / s12630-008-9020-7. Epub 2009 Jan 7.

study demonstrating that intranasal administration of naphazoline can significantly improve post-operative clinical conditions in patients undergoing maxillofacial surgery, reducing analgesic consumption

NAFAZOLINA AND PALPEBRALE PTOSI

Acta Neurol Scand. 1993 Apr; 87 (4): 322-4.

Work that evaluates the therapeutic efficacy of naphazoline in the eye area, demonstrating how this drug can be effective in the treatment of myopathic ptosis, even when taken occasionally.

THE POTENTIAL SIDE EFFECTS OF NAFAZOLINA

Clin Toxicol (Phila). 2008 Mar; 46 (3): 254-6.

Study reporting the occurrence of side effects such as acute pulmonary edema associated with the systemic effects of nafazoline, unintentionally ingested.

Method of use and dosage

RINAZINA®

Nashazoline nitrate 0.1% nasal spray.

It is advisable to spray the product 1-2 times a day as needed without prolonging the therapy beyond 4 days, in the absence of a medical consultation.

Warnings RINAZINA ® Nafazolina

The presence of a vasoconstrictor such as Naphazoline requires great caution in the use of RINAZINA® especially in patients with hypertension, cardiovascular pathologies, renal pathologies, glaucoma, in elderly patients and in pregnant women.

Prolonged topical use of sympathomimetics could result in addiction, significantly reducing its clinical efficacy.

PREGNANCY AND BREASTFEEDING

The use of RINAZINA® during pregnancy should be limited exclusively to cases of real need and under the strict supervision of your doctor.

Interactions

The patient on antidepressant medication should avoid the use of RINAZINA® throughout the therapeutic process and up to two weeks after suspension.

Contraindications RINAZINA ® Nafazolina

The use of RINAZINA® is contraindicated in patients who are hypersensitive to the active ingredient or to one of its excipients, in patients with cardiovascular diseases, hyperthyroidism and glaucoma.

Contraindications to the use of RINAZINA® also extend to children under the age of 12 and to patients on antidepressant therapy.